United Therapeutics (UTHR) 3 May 232023 Q1 Earnings call transcript

Good morning, and welcome to the United Therapeutics Corporation First Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator today. [Operator Instructions] Please note this call is being recorded. I would now like to turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Thank you, Danielle, and good morning. welcome Earnings the Webcast. to First Therapeutics pleasure XXXX Quarter my you United to Corporation It's Accompanying on me today's call are Dr. Chairperson Chief Edgemond, of Technical our our Pat Poisson, and Rothblatt, and and Vice Officer; then Executive Martine President Executive Michael Treasurer; President and and Chief finally, Operating our James Operations; our Officer; Financial Officer Chief Benkowitz, Dr. of Leigh Peterson, our Product Senior Development. Vice President

may forward-looking regarding risks will include statements actual that future and These today expectations beliefs representing differ Remarks or to involve events. statements uncertainties materially. cause results our

Our contain statements. latest no risks and and SEC filings, forward-looking including assume Forms and additional XX-K XX-Q obligation we these these information update to on uncertainties,

remarks products the that suggest information any or or are or intended investigational serve remarks Today's basis of uses. are the effective product's with not any results products to these products. available and clinical decision-making other investors for prescribing educate for as intended safe These and may solely website. trials to and unapproved are also respect to discuss Full progress developments on to the our medical are for

I first Now results XXXX webcast turn the Rothblatt to Therapeutics. and United activities Martine? quarter business of financial of overview will for an Dr. the our over

Dewey. at excited another you, everyone great welcome United to Thank Very to quarter Therapeutics.

on We revenue our of goals of are run for our towards and rate. continue thrilled doubling the XX,XXX pulmonary to mid-decade course patients hypertension being treated

growth also 'XX growth from main XX% This quarter, includes, is in nearly quarter revenue way, And those which Tyvaso. we the growth first double-digit driver, toward first with by quarter moved to goals 'XX. that our

sotatercept Liquidia. sotatercept new even hypertension. growth solid The FDA reason double-digit pulmonary even a III market approvals tested has Group our our been not forecast think that in with main of the I remains is possibility of or growth of rate

be are we In Group complementary perfusion drugs to was causing arterial expect generally I pulmonary hypertension, or disease products. to them the or Orenitram, our due in, contraindicated Tyvaso mismatch. VQ it systemic Remodulin there to Tabarcept either Indeed, ventilation tested

to our don't So we forecast a growth. from sotatercept, threat realistic

Liquidia, growth is because a does XX% instead if own challenge drug but effect Sales a based our even is approved, Tyvaso's not of drug match in more clinical also requiring data. product to it device not product, generic strongly on is projected trial their differentiated double-digit

Also the progress exciting our report to this quarter robust is in pipeline.

there than their are spot trials Tyvaso pipeline kits. titration from Phase our now current In doubling our market, Remunity the by the our year, to end total billion words, more potential. next products revenues, target enroll of have the fully such already III We own our organic on DPI, then other is the double of each aforementioned revenues new of Orenitram big $X and and and embeds current our as existing now entering commercialized which dose

to big use excited very the front. report news on also of capital I'm

clinical Xeno We have Search $XXX our facility Carolina, manufacturing Tyvaso the North way, in by transplantation is to allocated $X.X billion capital with million in DPI to existing our patient of Triangle to And XX,XXX a new addition allocation nearly this capacity. in new Virginia. facility Park,

update to By Quest. of story thank transplants everyone Silversea's Amy face immunosuppressants. of her doing me we United heroism wanted I'd our are the the other what a speaking at heart the that Amy's take who sent moment and transplant, on to In to of about effectuate Therapeutics shareholders superb I like vein, way, in stakeholders dozens and to

alveolar from cells or two cells. we'll stem epithelial cells of patient of we In called cells patients be differentiated organs, such reprogrammed cells. end stem stromal different to In our of labs, as including creating we pluripotent our cells from into need By own own the and differentiate types inducible year, lung, month. back cellularizing different donors IPSCs for of cells line types company, cells this every IPSCs and different single

our labs, past cells cells three needed year. trillion have billions produced every in years differentiated we and to into the of XD cover own the about changes we in grow our two over own labs cells In each organ

cellularize lung Also in lungs, a Indeed, that our the organ with level own of considered month, of our for expanded. achieved scaffolds own kind ox cells last concept have for of one level of with model pig transplants. labs, our we provided acceptable we the human we of a cellularized proof

in labs, Systems. an lung scaffolds Again, for every GMP transplant immunosuppressant this time conditions Amy's decade, kidney this organ about with XD and produce the year scaffolds printing XXXXs. we own short, are XD working free In is under on in XXX and of partnership liver realistic our now vision

as at immunosuppressants would be United needed within have the years. autologous a and to stem lungs, in differentiated will organs same we though also patient-derived the cell livers five patient. could Here expect kidneys Therapeutics, the be DNA Parts clinic done, have transplanted because

at and the here Therapeutics another is $X $X.X times pipeline expansion. quarter; record and business United revenues, of really it deployment record of capital So opportunities; billion best potential, record with billion-plus

our or is mantra big UT, go At go home.

big We hypertension. pulmonary on are going

business. Chief pulmonary are big give we you tolerable Operating deeper are Officer, going We dive on transplantable, of fibrosis. on Michael our organs. unlimited supply Mike? into Benkowitz, And President a will big creating the going an and now

report $XXX said, We're Martin, second treprostinil history. morning, more our time our than million meaningful yet company's Thanks, the excited pleased in revenues of to really for quarterly and we're have of quarter to growth as another everyone. for And business. good Martine

treprostinil Remodulin each As usual, provide around our with color going what to I'm to Tyvaso, some Orenitram. and we're seeing products, respect of

strong DPI, physician a trends the Tyvaso at active patient we to in and and quarter with as consistent continue patients three for exceptionally quarters. Tyvaso grow the our prior demand patient Tyvaso remained underlying first clip the for For growth Tyvaso

We number is and during call saw a which patient referrals, starts quarter. record the we prescriptions new what of first

is the base. continue prescribers. PH-ILD metric to launch terms of of our the prescriber in on more that in and here also prescribing depth, That's calls or And prescribers prior breadth doubled number breadth depth metric. Tyvaso now Since patients. three have of Tyvaso with We XXXX, I've our mentioned of Tyvaso increase we the number the key the

I'm also all in report which represent should which really the to category. X-plus to of an this prescribers Tyvaso way that of accelerate about The over XX% expand we've number we now growth still prescribers depth, doubled means Tyvaso prescribers, to happy time. the opportunity have pave further

with for quarter March in as respect and the first year usual, February, performance to patient discontinuations normal The usual April. changes to and levels Tyvaso insurance early in due discontinuations returned to seasonality saw also

well Tyvaso, nebulized Tyvaso with for DPI. patient reflecting Importantly, of discontinuations below to Tyvaso DPI satisfaction run that continue

the So Tyvaso believe strength the great. underlying is overall, of business we

the Looking encourage to said at longer-term in the we're and to our of three first we impacted said, given Tyvaso revenue middle in in compared regularly main then within first quarter past, that trends due quarter, Tyvaso revenue launches to factors revenue, at that of revenue the franchise, look essentially business, product investors nature Tyvaso fluctuations. DPI. quarterly PH-ILD that as I With two the there were the

rightsizing orders appreciating quarter, increased last for of First, correct anticipation our and as year, potential the nebulized fully discussed of without quarter the In and we made DPI specialty DPI of specialty demand. orders significant pharmacies PH-ILD demand are pharmacies Tyvaso third the mix. nebulized for last in still Tyvaso

in for this of demand this well the patient we year, last reduce DPI first quarter nebulized quarter under quarter saw actual fourth Tyvaso reduced -- demand relative the of and Tyvaso. inventory, needed revenue pharmacies first patient its to the year Tyvaso XXXX well strong and to the of nebulized specialty quarter unexpectedly of Moving to year. And the which fourth under

a to when for than year. starting are Medicare Second, inflation a at is large go and degree next level Tyvaso the into seeing changes we're We PAP that subside of this higher of effect utilization believe we will phenomenon short-term part a the DPI reduction expected.

Having demand of something that, the the year. demand up minimum DPI to incredible immediately both the we Finally, in this we to term. have due our pharmacies capacity their fact and building each to contractual on not balance to approval the persist medium inventories trends able DPI are that could steps production month. upon and allow short launched to specialty that is we increase forecast, taking DPI for inventory, without said been Based for and the

additional soon as as MannKind, a First, production activating partner, which supply second quarter. is from capacity we DPI and kitting line our this see increased to expect

year. Second, first the parallel, to on a MannKind track half of also support up in and to in manufacturing is Tyvaso significantly patients DPI capacity year to XX,XXX next expand

XX,XXX to capacity construction XX,XXX Martine patients. year manufacturing as initiated That we a provide new DPI mentioned, expansion finally, facility for to capacity an and a Tyvaso per owned to is DPI with and to project support operated UT have intended And up facility. additional patients enough build DPI

back in starts, competitor Turning We faced subcutaneous available of market This though levels. Remunity gain the active our Remodulin And to launch Remodulin to representing shipments half quarter. for during years widely are after almost with new referrals active subcu resilient, first a number for over the following of in saw in now. subcutaneous the Remunity four patients patients is highest Remodulin to our pre-generic Remodulin, of patient continues dip business incredibly generic the quarter. Remodulin. even it's the small for be a to generic second a it version traction continues as only of monthly pump the

record a achieving revenues. of and patients launched a for a kit had the patients. XX-day new therapy very Orenitram record titration during We which Finally, first on and quarter, titration number simplifies dosing quarter, solid

has physician early, very these still been kits. new While the and patient around positive convenience feedback of

the oral average we Remodulin in not top-lined to time lot a compared double to as to around demonstrating lead be dose shorter patients therapy patients do to when who Orenitram induction continues buzz have Remodulin There data induction. prostacyclin in physician the last and a expedite shift can a the community October, of of with period that

the a the detailing publish We to peer-reviewed manuscript coming expect months. in study

a Treprostinil to run goal we're and To Martine the rate. Q&A With with demand our way DPI, pleased wrap call to led very the incredible over session. we to that, the by overall we're $X hitting business, revenue start I'll back billion Tyvaso our on of the believe for turn up,

so you We with Mike. were one terrific much, of Those the call products. every into Thank everyone. that you that insights shared take

please questions most the you the I appropriate and the will phones, sort open could them. to Operator, for answering person

comes TD question Joseph of first The Instructions] Cowen. [Operator Thome from

expect the for lower the that time bit mentioned average with versus the you Maybe you what next discontinuations nebulizer? sotatercept what actually are without of did what And they are ramp patients sotatercept? to Tyvaso the time with could continue little Tyvaso maybe launching know we seeing maybe year, a do nebulized that than increase of seeing would better expect Or down on How Tyvaso. DPI Tyvaso therapy kind as intend on see than maybe you these to their were use? as potentially therapy out? I were DPI you do the kind play you Mike, the do expectations they

Looks you. like direct to question this

Sure.

still So think that, level really on by of And put that, the has discontinuation number lower going been a therapy. of to what But that satisfaction increased patient we're a I definitively to rates overall, Tyvaso DPI. think on early a with really that's for think augurs To well say do it's encouraged kind certainly, little Tyvaso we be. with high time I DPI.

adherence, and patients think will longer. then better lead to it's and doing therapy compliance better leads better, to on ultimately to I patients that led staying that

certainly right. increase And that absolutely your think time your that's I expecting. will over on time therapy So with premise, we're is hypothesis something DPI

I sotatercept as think regard helps Similarly, that probably well. in

sotatercept If XX% were the at you on that background of the the patients study data in study, prostacyclin. and underlying look a

there's So think and we as in opening lot her prostacyclin sotatercept. a comments, complementary said between effects of Martine

expect products therapy when background as a And lead patients continue the would sotatercept continue time and other that experience as nice that launched benefit the so market, well to two should the we will to between increased will into therapy. is and on products on

next Operator, Mike. question please. Thanks,

Singh of comes Next question Oppenheimer. from Hartaj

update Nice everybody.

at again, had really educating community. Just you ATS at delve there big like this the It of in kind Barcelona last and that. a question ERS into year updates know patient/physician year, in EXPEDITE study. I the on OrCam will seems

just going patient a is. flow us Are can the breakdown? you Or and to starting what If then talk little Orenitram? bit and are what's patients to mostly they about starting over the Remodulin, Orenitram still in

we expect that of already I more to that could Orenitram even forward? forward? know it And then going but can add is, going benefit how sort

be, you'd think best Great question, the question. Mike, to Hartaj. person I that again, be address

for Hartaj, the Thanks, question. Sure.

patients XX starting call are So starting two-thirds in it, kind Remodulin, the mix of -- Orenitram patients it's roughly, terms transition now. and of I of think de roughly, between Orenitram two-thirds of from novo right

patients And to that titration transitions de I on got I continue as comments, new think mentioned novo, are going my kit, the Remodulin. up titration fact to -- help I then and that's the we've balance in starting think that Orenitram titrate from

still I proving think, be is and that patients be I to will I convenient EXPEDITE will there fully, gateway for novo it's we believe of DPI of your But will or sort that really patients, also the so think prostacyclin. there time Tyvaso data. over it's Orenitram start take to be that de drug almost true once advantage

patients So to DPI the I and prostacyclin selexipag. think over therapy see number percentage time, -- on Orenitram initiate even you're of going higher orals, a over higher both

start closer to use to down to an Orenitram drug, hemodynamic ARTISAN levels. we really which III their then Orenitram the then of or so as the them about you on titrate as these can the prior maybe even get data case is opportunity patients Remodulin, Class functional IV And on patients it's and the continue need. flip we've to that Artisan, study, talked to hemodynamics up about and maintenance in And normal you them thing their like over take EXPEDITE really calls and

and over of And sort different in But it options. speaks they got as we've you as key several next if kind move continue time, decline, really that just of And flexibility these them delivery we Remodulin. to Orenitram the the years. that see a switch fact for position obviously really can -- they over forward of to treprostinil back the some, we

And really the is us their kind and just, the allows think, it of physician patient progression. in where to the so I patient meet disease

out describe the around, able millimeters patients and into EXPEDITE was you And with XX would pulmonary the with so to beautiful much, get will, say, that like Thanks volume data of Great. We're there. Mike. down to really I That a oral. way mercury. an the and stable increasing rapid there's pressures ARTISAN transition able whole you're equilibria, artery below if of to

data limit out the of very XX hypertension over by mercury that pulmonary shown have -- the that had those XX, to in between Well physicians, long-term us. achieve dozen access who years scientific papers papers from survival, to XX a potential millimeters XX are with And are the papers and the of to. of independent kind managed of are not paper patients able well that this

rapidly mission of company and achieved been from parenteral with to with Operator, to really their we prostacyclin, to pressures able the oral pulmonary hypertension largely very keep So of the patients believe hypertension able that of in them being stable down long then next our pulmonary initial prostacyclin of keep term. with the living to instead combination dying Orenitram question. has get pulmonary hypertension be

Fye Jessica The next JPMorgan. from question comes of

is you But it confirm to just increase as capacity sounds patient sounds And demand that On Tyvaso with the bullish to like adds? plans any capacity near then can the adds seeing constraint that's is target trends that well. there. capacity net just patient right now there's and keeping at nice the term, patient reaching in for to DPI, up respect you're pretty on it demand you're pharmacies anticipated levels? whether the specialty with inventory the Or keeping limiting all from DPI maybe

just you're you related run adds quarters. just net tracking line patient was the think said in rate with to remind Can past three you with. that And what were that, I Tyvaso that me in-line

your questions, There this much to several were and so morning. good Thanks questions Okay. there. the for Jess, hear voice

that there. could then, production start expansion So let Jess if your the And to the you queue asked rest up the questions with responses me Mike, of questions.

maximum by DPI Danbury, will and XX,XXX facility for the in on Jess, are bullish Connecticut, of MannKind next our So of will beginning DPI the patients. up be forecast the for pretty capacity Tyvaso we year, be

for So be a we'll capacity entering 'XX patients. with XX,XXX

patients. XX,XXX as introductory Now pulmonary company's middle my mentioned of treat decade able hypertension -- remarks, for the XX to in being the are I goals our

on large production XX,XXX for are a if pulmonary would on the the like, DPI, So the we I market well, is, reasonable, patients fibrosis, go fibrosis will where then capacity be it big think, for think is what pulmonary be. which whereas of the Tyvaso capacity production proportion those

we actually as market. than to fibrosis pulmonary pulmonary can market the DPI best be Well, the even for expect larger hypertension tell, Tyvaso we

So market expect an pulmonary more fibrosis and we is pulmonary fibrosis XX,XXX hypertension to XX,XXX in that to pulmonary we the XX,XXX the for mid-decade and such we than in capacity have that would easily the addition additional need have market Tyvaso patients. research disease-modifying for patients hypotheses patient being treated fibrosis indeed, the pulmonary could DPI

amount to this facility now build reason the production Research Carolina. substantial a North DPI capital need deploying in we start that's Clinical So Park, to Tyvaso of brand-new why

even capacity As to a patients. patients, Mike mentioned, though have will its go even be that capacity will facility, it surge to up XX,XXX launch XX,XXX

I for we additional to fibrosis, embarking So progressive to surge -- Carolina, pulmonary then trial on idiopathic in XX,XXX between under other patients at in cover hypertension, hypertension, fibrosis we proliferative enter XX,XXX both XXX,XXX capacity DPI frame, XX,XXX fact, support we XX,XXX the a pulmonary forms and III for. Group rubric have which the Phase to XXXX think pulmonary we in the would which additional time fibrosis as the the needs the MannKind, North North of are our that pulmonary of pulmonary III Group go Carolina,

you terms So Mike, the with that answer of other those the had? production Jess capacity, questions comments can in

Absolutely.

demand to was your their part around first question -- So of up Jess, of sort first inventory. I patient demand versus around build think your your question SP

definitely we're the it's -- the latter. So of category in

demand. So to starts the We're patient on having delay to DPI. enough patient we're meet not making

They specialty they have, call to in much to how an on month. and up days. referencing it, over try was to -- algorithm get order down have for typically of my month, the two order opening pharmacy, inventory I about that is XX course issue roughly the out they months of how the then hand typically, think figuring every they'll I comments

So -- have at always they a days in hand. generally like least on of minimum XX where a they at keep to be position inventory

the between capacity we're will to additional I said, not over open Like not part really -- situation demand, up be able up have as accustomed they're things pharmacy. next to ordering that bit. to order soon grow levels as the the quarter. we the to as able where specialty in So we're year get they're continuing to to due this to online of kind to going be That I to to production balance Martine to of we going we're some the get start year, probably this until, of up But meet patients. need up significant as on said, that XX,XXX expansion the little think to a the coming

Second patient your the part just I question run of rate of in adds. of the was sort terms guess, average,

if on around look it's -- quarters, over this between and So and Tyvaso, averaged three up quarter back kind you last that's XXX prior the adds quarter patient nebulized. both of per the and DPI to

Mike. your for ready next question. we're . Perfect, Operator, so Thanks much.

question comes Yang Eun from The next from Jefferies.

I have TETON a question on trial.

So expecting we data XXXX. in are

based So Phase on patients XX to up of we saw subgroup weeks. a trial, on increase III underlying benefits IPF, the FVC with

XX-week TETON point. trial So is a time

increase on benefits trial. expect can weeks? to you continue XX do you comment on to the powering then TETON So for assumptions FVC And to

hear Nice questions. Eun. to morning, Good Thanks. your

questions. to have of Dr. in is trial answer be charge will think TETON She it your best Peterson. I running

question. study, you so you in INCREASE the Yes, as mentioned. placebo-controlled for study, Yes. the XX main study, weeks, indeed, your the was fact, Thank

increased period. of the period data see study have including over open-label how do longer XX-week the do where the of time time, we However, to patients extension looked we've an the

on we population. see the benefits in increased Tyvaso And of patients still

studies TETON feel And longer we've So FVC. the absolute the that as they to that we studies. have we to XX% translate the powered, detect seen that, period will the far with I regard as definitely in mean, to difference TETON power the studies, confident increased in are

period. have So we difference the power the sufficient XX-week to see over

feel confident that. we again, So on

It's for very Operator, we much, are Leigh. next awesome. question. Thank so your you ready

of Andreas from The Argyrides next comes Securities. Wedbush question

first, what's first the programs? manufacturing? when manufacturing on When how to thinking we And when trial? the comes we of it quarter. one Congrats so then spend about status the And follow-up. And -- think I expect organ have organ clinical can quickly, should

your quarter. Okay. and We be congrats follow-up, won't take to the Andreas on able

up clinical when overview the the gist little of broke get of question we line organ into I situation trials. was an Your the a and but organ to to manufacturing manufacturing bit, the of expect think results enter

associated I something asked you spending. other capital the think And about with

So manufacturing Gold program broad, a on is shots the multiple programs. multifaceted, organ

So exciting our passionate things an realistic of not give to would that strongly part any that beyond response be mentioned overview really on organs everything manufacturing it teams I that program of won't silver the this to arguments morning require really immunosuppressants. in is focused organ

company other autologous different with are cells. iPSC Therapeutics, United organs differentiated words, techniques we the cells a reprogram from types cells. into And to and own into proprietary cells. those cellularize downstream then manufactured In at laboratories to donated within with. then patient's patients PBMCs words, cells We organs we other cells we produce the of that the that different In cells -- another currently we would from stem back stem differentiate used

allogeneic able to other we programs are lines laboratories segment. at Therapeutics are based United MHC Other cell on that within

lighter organ. average just kind taking expect much load donor immunosuppressant a So they patients could of than were if an

get question And then to let about the trial. me clinical your

clinical donor So been practices animals of manufacturing the the whether hearts closest that are from our These good under are kidneys hearts pathogen-free conditions. kidneys. we Xeno called trials grown and have organs to Xeno and have conditions, equivalent

be able today they of and is allografts. as the chronic in And them will immunosuppressants surmount a the today, duration body recipients modifications to with continue to XX we allow to acute on long-term genetic commercially more believe with no hyperacute the have rejection normal done available rejection with and than that management

the the program first be last able into complete -- be 'XX study. by program those called trials in by the That end that hopefully, preclinical FDA into currently enter we And able and in So of is program will human the clinical going to then means organs to what's a pivotal that are it's a preclinical before program. 'XX.

So kind to one question to wood, into enter should of question. that manufactured last your first a trials we've Operator, answer in the would clinical for 'XX. hearts hopefully. Knock got line be kidneys bottom able be and time at on

Verma comes The next UBS. from of Ash question

one on had sotatercept I impact.

the feedback reception positioning? impacted. the indicates heard for and pricing get So part on view, portfolio does In payer that And bearing have of we've of Merck's on that physicians product your therapy that in an competitors' matter? important can positioning assumptions your may that line have what is like what you

the question provided whatsoever Okay. noted effect and I a for Like But an on guidance the remarks, don't of definitive frontline our we've Thanks for questions, Ash. more Mike give answer. introductory sotatercept as in will a see any you growth we that having Mike company. our that answer,

with reason to as the drugs easy diseases is clear that very are such a for people sound it's that that And similar are lot treated two confused. that get ours different are there of them and not completely

the for So is hypertension, disease PAH. our the drugs for called that Group and in all our approved are and was tested that non-cancer I the is all disease of pulmonary are arterial drugs acronym approved of sotatercept

different or pulmonary Group A is Group just called II disease III hypertension PH.

Group III we're never III Group is aware Sotatercept published hypertension. least that of, only been for drug Tyvaso Tyvaso, anything has approved in DPI. pulmonary pulmonary including The tested, at hypertension

growth pulmonary Group our years, come of we expect the most well, coming hypertension. very III described Mike in to as from And

on cannot that growth trajectory effect whatsoever. definition, have sotatercept any by So

pulmonary In be ever, where do think that, of sales mentioned sotatercept have Orenitram arterial addition expect our growth had across highest the complementary. to continue within quarterly we Mike to I I we we franchise, to group hypertension, our

on that? And Mike, to would you expand like

drugs up which look is, It's drug currently to to drug there, and another different have hypertension. earlier Sure. pulmonary are the think we to as to to response four an market on arterial pathways, with this, I I associated I pick treat pathway our other the a I'll just PAH. that in kind right at sotatercept now said treat complementary of around question definitely we Group

were said, at of If the in patients XX, you those look -- if I look the trial, at sotatercept as the data prostacyclin therapy. X-X, XX% you on

a appears complementary sotatercept. and to be synergistic clearly, So or there between effects prostacyclin

think of will we be drugs continue all So that to used. the

four -- some talked physicians the of that in gets have of a still doesn't think progressive it's I pathways. about, How approach really to in a drug treat sort Four you matter the things really or suggest to scheme each I this that sequenced PAH, treating talked sotatercept to agent. and Corners grand nothing think There we've a a that because so have data cure of of disease. the disease-modifying even was it's

I know the borne there that's that out think but was data. some speculation don't case, I that, might the be in

with So it, other a but combination clearly, patients it's I drugs. are benefiting from think the

that's going our replace rematarium, doesn't appear to And physicians something but to it's so we treatment on or displace think over time, another drug be products. that can add their to it

thank color sundry seeing you look United our during everybody, providing to business. Thanks presenting you of the and and so and various conference work insights of year, And call. health first additional and conferences Dewey can on operator, joining much, at forward Mike. We'll Steadman. quarter great and be for we care Operator, The the disconnect there balance Therapeutics call. the you,

for you Investor in Relations and participating Events for Thank will United Presentations this United Therapeutics website visiting today's for earnings Corporation the week by replay webcast. available of rebroadcast section one of be @ir.unither.com the Therapeutics webcast A